Sign in
CompletedPhase 1

A Phase 1 Study to Assess an Escalating Dose, Multi-prime Vaccination Schedule of R21/Matrix-M™

Key facts

Who runs it
University of Oxford
Where
United Kingdom2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 1
People taking part
36 people enrolled
Started
25 Mar 2024
Ended
1 Sept 2026
Type of study
Interventional, 3 groups
Treatments tested
  • R21/Matrix M™ (Group 1)
  • R21/Matrix M™ (Group 2)
  • R21/Matrix M™ (Group 3)
  • Fine needle aspiration (FNA)
Record updated
21 October 2026

Who can take part

Age
18 years to 50 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Healthy adult aged 18 to 50 years
  • Able and willing (in the Investigator's opinion) to comply with all study requirements
  • Participants of childbearing potential only: must practice continuous effective contraception until the last study visit
  • Agreement to refrain from blood donation for the duration of the study
  • Able and willing to provide written informed consent to participate in the trial

Who cannot take part

  • History of clinical malaria (any species) or previous participation in any malaria vaccine trial or controlled human malaria infection trial
  • Prior receipt of an IMP likely to impact interpretation of the trial data, as assessed by the Investigator
  • Receipt of oral or systemic immunosuppressant medication for more than 14 days in the six months preceding enrolment
  • Positive Hepatitis B surface antigen (HBsAg), HIV antibodies or Hepatitis C (HCV) antibodies (except previous HCV vaccine study participants)
  • Receipt of any vaccine within 30 days of a study vaccine, with the exception of COVID-19 vaccination
  • History of anaphylaxis to vaccination, or allergy likely to be exacerbated by any component of the vaccine or study procedures, including allergy to lidocaine
  • Clinically significant history of chronic disease, including cancer (except basal cell carcinoma or cervical carcinoma in situ), immunodeficiency (including HIV), autoimmune conditions (except mild psoriasis, well-controlled autoimmune thyroid disease, vitiligo or stable coeliac disease), psychiatric disorder, drug or alcohol abuse
  • HEMStop score > or = to 2(30) with abnormal coagulation screen or clinical concern regarding bleeding risk
  • Use of medications that increase the risk of bleeding, as assessed by the clinician, including: warfarin, oral antithrombin agents (e.g. Apixaban), low molecular weight heparin
  • Any other significant disease, disorder, or finding, which, in the opinion of the Investigator, may put the volunteer at risk, affect the volunteer's ability to participate in the study or impair interpretation of the study data
  • Travel to a clearly malaria endemic locality during the study period or within the preceding six months, as per the CDC website: https://www.cdc.gov/malaria/travelers/country_table/a.html
  • Participation in another research study involving receipt of an investigational medicinal product (IMP) in the 30 days preceding enrolment or 5 half-lives of the investigational medicinal product, whichever is longer, or planned participation during the study period
  • Receipt of immunoglobulins or blood products (e.g. blood transfusion) in the three months preceding enrolment
  • Pregnancy, lactation or intention to become pregnant during the study
  • Any clinically significant abnormality of screening examination, blood or urine tests
  • Participants unable to be closely followed for social, geographic or psychological reasons
  • Investigator inability to corroborate a participant's medical history via access to NHS electronic records and/or their GP

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a phase I clinical study that aims to assess the safety and immunogenicity of a novel, escalating dose regimen of R21/Matrix-M™ in healthy, malaria-naïve adults.

The 3 groups in the trial

  • Group 1: Escalating dose R21/Matrix M™Treatment being tested

    12 volunteers receiving escalating doses of R21/Matrix M™ adjuvant at days 0, 3, 7, 10, 14, and 56 via intramuscular (IM) injection in the deltoid region of the same arm

    Treatment: R21/Matrix M™ (Group 1) and Fine needle aspiration (FNA)

  • Group 2: Escalating dose R21/Matrix M™ with delayed boosterTreatment being tested

    12 volunteers receiving escalating doses of R21/Matrix M™ adjuvant at days 0, 3, 7, 10, 14, 168 (subgroup 2A)/280 (subgroup 2B) via intramuscular (IM) injection in the deltoid region of the same arm

    Treatment: R21/Matrix M™ (Group 2) and Fine needle aspiration (FNA)

  • Group 3: Standard dose R21/Matrix-M™Treatment being tested

    12 volunteers receiving two 10mcg doses of R21 in 50mcg of Matrix M™ adjuvant at days 0 and 56 via intramuscular (IM) injection in the deltoid region of the same arm

    Treatment: R21/Matrix M™ (Group 3) and Fine needle aspiration (FNA)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1 Study to Assess the Safety and Immunogenicity of R21/Matrix-M™ Administered in an Escalating Dose, Multi-prime Vaccination Schedule in Healthy Adults
Record updated
21 October 2026